Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

被引：181

作者：

Herbst, Roy S. ^{[1
]}

Gandara, David R. ^{[2
]}

Hirsch, Fred R. ^{[3
]}

Redman, Mary W. ^{[4
,5
]}

LeBlanc, Michael ^{[4
,5
]}

Mack, Philip C. ^{[2
]}

Schwartz, Lawrence H. ^{[6
]}

Vokes, Everett ^{[7
]}

Ramalingam, Suresh S. ^{[8
]}

Bradley, Jeffrey D. ^{[9
]}

Sparks, Dana ^{[10
]}

Zhou, Yang ^{[1
]}

Miwa, Crystal ^{[10
]}

Miller, Vincent A. ^{[11
]}

Yelensky, Roman ^{[11
]}

Li, Yali ^{[11
]}

Allen, Jeff D. ^{[12
]}

Sigal, Ellen V. ^{[12
]}

Wholley, David ^{[13
]}

Sigman, Caroline C. ^{[14
]}

Blumenthal, Gideon M. ^{[15
]}

Malik, Shakun ^{[16
]}

Kelloff, Gary J. ^{[17
]}

Abrams, Jeffrey S. ^{[18
]}

Blanke, Charles D. ^{[19
,20
]}

Papadimitrakopoulou, Vassiliki A. ^{[21
]}

机构：

[1] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA

[2] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA

[3] Univ Colorado, Dept Med Oncol, Hlth Sci Ctr, Aurora, CO USA

[4] SWOG Stat Ctr, Seattle, WA USA

[5] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[6] Columbia Univ, Dept Radiol, Coll Med, New York, NY USA

[7] Univ Chicago Med & Biol Sci, Dept Med, Chicago, IL USA

[8] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[9] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA

[10] SWOG Operat Off, San Antonio, TX USA

[11] Fdn Med, Cambridge, MA USA

[12] Friends Canc Res, Washington, DC USA

[13] Fdn Natl Inst Hlth, Bethesda, MD USA

[14] CCS Associates, Mountain View, CA USA

[15] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA

[16] NCI, Ctr Canc Res, Bethesda, MD 20892 USA

[17] NCI, Canc Imaging Program, Bethesda, MD 20892 USA

[18] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA

[19] SWOG Grp Chairs Office, Portland, OR USA

[20] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[21] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 07期

基金：

美国国家卫生研究院;

关键词：

SELECTIVE INHIBITOR; CLINICAL-TRIALS; ONCOLOGY; PALBOCICLIB; ALECTINIB; GENOMICS; AZD4547; TARGETS; POTENT; BAR;

D O I：

10.1158/1078-0432.CCR-13-3473

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The Lung Master Protocol (Lung-MAP, S1400) is a ground-breaking clinical trial designed to advance the efficient development of targeted therapies for squamous cell carcinoma (SCC) of the lung. There are no approved targeted therapies specific to advanced lung SCC, although The Cancer Genome Atlas project and similar studies have detected a significant number of somatic gene mutations/amplifications in lung SCC, some of which are targetable by investigational agents. However, the frequency of these changes is low (5%-20%), making recruitment and study conduct challenging in the traditional clinical trial setting. Here, we describe our approach to development of a biomarker-driven phase II/II multisubstudy "Master Protocol," using a common platform(next-generation DNA sequencing) to identify actionable molecular abnormalities, followed by randomization to the relevant targeted therapy versus standard of care. (C) 2015 AACR.

引用

页码：1514 / 1524

页数：11

共 50 条

[21] Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN)
Roth, Joshua A.
Trivedi, Meghna S.
Gray, Stacy W.
Patrick, Donald L.
Delaney, Debbie M.
Watabayashi, Kate
Litwin, Paul
Shah, Parth
Crew, Katherine D.
Yee, Monica
Redman, Mary W.
Unger, Joseph M.
Papadimitrakopoulou, Vassiliki
Johnson, Judy
Kelly, Karen
Gandara, David
Herbst, Roy S.
Hershman, Dawn L.
Ramsey, Scott D.
JCO ONCOLOGY PRACTICE, 2021, 17 (11) : 692 - +
[22] Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer
Gonzalez-Kozlova, Edgar
Huang, Hsin-Hui
Redman, Mary
Herbst, Roy
Gettinger, Scott
Bazhenova, Luda
Xie, Hui
Patel, Manishkumar
Nie, Kai
Harris, Jocelyn
Argueta, Kimberly
Kelly, Karen
Cerami, Ethan
Lindsay, James
Yu, Joyce
Biswas, Roshni
Van Nostrand, Stephen
Moravec, Radim
Del Valle, Diane Marie
Kim-schulze, Seunghee
Gnjatic, Sacha
CANCER RESEARCH, 2022, 82 (12)
[23] Conduct of a precision medicine trial: screening, tissue adequacy, study registration, and reasons for not participating on lung-map (lung cancer master protocol)
Griffin, Katie
McDonough, Shannon
Miao, Jieling
Moon, James
Redman, Mary W.
TRIALS, 2017, 18
[24] SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)
Borghaei, Hossein
Redman, Mary W.
Kelly, Karen
Waqar, Saima N.
Robert, Francisco
Kiefer, Gauri J.
Stella, Philip J.
Minichiello, Katherine
Gandara, David R.
Herbst, Roy S.
Papadimitrakopoulou, Vassiliki A.
CLINICAL LUNG CANCER, 2021, 22 (03) : 178 - 186
[25] Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G
Owonikoko, Taofeek K.
Redman, Mary W.
Byers, Lauren A.
Hirsch, Fred R.
Mack, Philip C.
Schwartz, Lawrence H.
Bradley, Jeffrey D.
Stinchcombe, Thomas E.
Leighl, Natasha B.
Al Baghdadi, Tareq
Lara, Primo, Jr.
Miao, Jieling
Kelly, Karen
Ramalingam, Suresh S.
Herbst, Roy S.
Papadimitrakopoulou, Vassiliki
Gandara, David R.
CLINICAL LUNG CANCER, 2021, 22 (03) : 187 - +
[26] Design, conduct, and analysis of a master protocol within an evolving landscape of standard of care: the lung-map trial
Redman, Mary
Moon, James
McDonough, Shannon
Miao, Jieling
Griffin, Katie
LeBlanc, Michael
TRIALS, 2017, 18
[27] A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub -study SWOG S1400C.
Edelman, Martin J.
Redman, Mary Weber
Albain, Kathy S.
McGary, Eric C.
Rafique, Norman
Petro, Daniel P.
Waqar, Saiama Naheed
Miao, Jieling
Griffin, Katie
Papadimitrakopoulou, Vassiliki
Kelly, Karen
Gandara, David R.
Herbst, Roy S.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Edelman, Martin J.
Redman, Mary W.
Albain, Kathy S.
McGary, Eric C.
Rafique, Noman M.
Petro, Daniel
Waqar, Saiama N.
Minichiello, Katherine
Miao, Jieling
Papadimitrakopoulou, Vassiliki A.
Kelly, Karen
Gandara, David R.
Herbst, Roy S.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1853 - 1859
[29] LUNG-MAP COMPOSITE SIGNATURE FOR IMMUNE CHECKPOINT INHIBITOR (ICI) EFFICACY IN ADVANCED SQUAMOUS CELL LUNG CANCER (SCC)
Gandara, David
Hua, Xing
Tolba, Khaled
Fabrizio, David
Albacker, Lee
Brennick, Ryan
Montesion, Meagan
Oxnard, Geoff
Adam, Stacey
Hirsch, Fred
Kelly, Karen
Herbst, Roy
LeBlanc, Michael
Redman, Mary
Wu, Michael
Kozono, David
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A31 - A31
[30] BIOMARKER-DRIVEN TREATMENT STRATEGIES FOR NON-SMALL-CELL LUNG CANCER
Okamoto, I.
ANNALS OF ONCOLOGY, 2012, 23 : 72 - 72

← 1 2 3 4 5 →